Incretin-based Therapy in Late Preclinical Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Type 1 Diabetes
Interventions
DRUG

Victoza®

Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.

DRUG

Placebo

Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.

Trial Locations (4)

20520

University of Turku and Turku University Hospital, Turku

33520

University of Tampere and Tampere University Hospital, Tampere

90029

University of Oulu and Oulu University Hospital, Dept of Children and Adolescents, Oulu

205 02

Lund University and Skåne University Hospital, Malmo

All Listed Sponsors
collaborator

Oulu University Hospital

OTHER

collaborator

Tampere University Hospital

OTHER

collaborator

Turku University Hospital

OTHER_GOV

collaborator

Skane University Hospital

OTHER

lead

University of Oulu

OTHER

NCT02898506 - Incretin-based Therapy in Late Preclinical Type 1 Diabetes | Biotech Hunter | Biotech Hunter